<DOC>
	<DOC>NCT01216072</DOC>
	<brief_summary>The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fingolimod vs. standard of care DMT.</brief_summary>
	<brief_title>A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Relapsing forms of MS Expanded Disability Status Scale (EDSS) 05.5 Continuous treatment with MS DMT for a minimum of 6 months Fingolimod naive Immune system diseases other than MS Active macular edema History of selected prior infections and criteria for immunizations History of selected immune system treatments and/or medications Selected cardiovascular, pulmonary, or hepatic conditions Selected abnormal laboratory values Pregnant or nursing women Other protocoldefined inclusion/exclusion criteria applied</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Relapsing Forms of Multiple Sclerosis</keyword>
	<keyword>Disease Modifying Therapy</keyword>
	<keyword>fingolimod</keyword>
	<keyword>Patient Reported Outcomes</keyword>
</DOC>